Extended systems medicine protocol to understand the development of psoriatic arthritis

Extended systems medicine protocol to understand the development of psoriatic arthritis - Extend-UP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43948

Enrollment

Registered

2015-11-17

Start date

2016-03-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Cohort Pso: N

Exclusion criteria

Exclusion criteria: Use of immunomodulatory drugs Contraindications to FDG-PET/CT, MRI scanner

Design outcomes

Primary

Measure	Time frame
-Integrative systems medicine profile will be derived from blood samples (RNA sequencing, micro RNA profiling, genome-wide methylation, flow-cytometry; same as in protocol 13-696), skin biopsies (immunohistochemistry and single cell sequencing), and microbiome (skin/gut 16S rRNA sequencing). -Established disease activity parameters will be assessed (e.g. joint count, enthesitis count, CRP) along with novel disease activity parameters aimed at detecting early (sub-clinical) changes in the joint/enthesis (i.e. MRI of the feet; whole body FDG-PET/CT). Group differences with respect to systems medicine profile and novel radiographic imaging will be compared between Pso and PsA (with AS serving as disease control group). The relationship between the early changes in the joint/enthesis (as detected with novel imaging) will be compared to the underlying molecular pathways (as detected by integrative systems medicine profile).	—

Measure

Time frame

-Integrative systems medicine profile will be derived from blood samples (RNA sequencing, micro RNA profiling, genome-wide methylation, flow-cytometry; same as in protocol 13-696), skin biopsies (immunohistochemistry and single cell sequencing), and microbiome (skin/gut 16S rRNA sequencing). -Established disease activity parameters will be assessed (e.g. joint count, enthesitis count, CRP) along with novel disease activity parameters aimed at detecting early (sub-clinical) changes in the joint/enthesis (i.e. MRI of the feet; whole body FDG-PET/CT). Group differences with respect to systems medicine profile and novel radiographic imaging will be compared between Pso and PsA (with AS serving as disease control group). The relationship between the early changes in the joint/enthesis (as detected with novel imaging) will be compared to the underlying molecular pathways (as detected by integrative systems medicine profile).

—

Secondary

Measure	Time frame
The prospective value of integrative systems medicine profile and (novel) disease activity parameters on disease course and response to treatment will be evaluated. Novel imaging techniques (MRI of the feet; whole body FDG-PET/CT) will be compared to established disease activity parameters to evaluate their complementary/additional use as disease-activity parameters.	—

Countries

Netherlands

Outcome results